Stryker Corporation
SYK
Positions held
Your positionsSYK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Stryker Corporation is well-positioned in the medical devices industry, benefiting from a growing demand for innovative healthcare solutions.
- In Q2 2026, Stryker's revenue increased by 9% compared to the previous quarter, reaching $6.6 billion.
- The company's gross margin improved to 68.3% in Q2 2026, up from 63.3% in Q1 2026.
- Despite its strong market presence, Stryker faces challenges with a recent sell signal indicating potential downward pressure.
- The company's score indicates a 'Sell' signal with a score of -12.00, reflecting a negative trend in its stock performance.
- Stryker's operating margin was 25.2% in Q2 2026, but this follows a decline from 25.3% in Q4 2025.
Fundamentals
| Market cap | $106.24B | Enterprise value | $118.21B | Trailing P/E | 28.70 | Forward P/E | 16.59 |
| PEG | 1.29 | Price / book | 4.43 | Beta | 0.78 | Dividend yield | 1.27% |
| Revenue growth | 9.4% | Earnings growth | 44.1% | Gross margin | 65.6% | Operating margin | 27.0% |
| Profit margin | 14.4% | ROE | 16.5% | ROA | 8.2% | Debt / equity | 0.64 |
| Current ratio | 2.16 | Free cash flow | $4.11B | Analyst recommendation | buy | Mean target | $366.15 |
| 52w high | $392.55 | 52w low | $267.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $6.6B | $6.0B | $7.2B | $6.1B | $6.0B | — |
| Op margin | 25.2% | 15.5% | 25.3% | 19.9% | 19.4% | — |
| Net income | $1.3B | $745M | $849M | $859M | $884M | — |
| Gross margin | 68.3% | 63.3% | 64.5% | 63.6% | 63.8% | — |
| Gross profit | $4.5B | $3.8B | $4.6B | $3.9B | $3.8B | — |
| Operating income | $1.7B | $936M | $1.8B | $1.2B | $1.2B | — |
- Revenue +9% vs prior quarter ($6.6B vs $6.0B).
- Gross margin 68.3% (was 63.3% prior quarter).
- Operating margin expanded to 25.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $25.1B | $22.6B | $20.5B | $18.4B | — |
| Op margin | 20.1% | 20.7% | 19.1% | 16.9% | — |
| Net income | $3.2B | $3.0B | $3.2B | $2.4B | — |
| Gross margin | 64.0% | 63.9% | 63.7% | 62.8% | — |
| Gross profit | $16.1B | $14.4B | $13.1B | $11.6B | — |
| Operating income | $5.1B | $4.7B | $3.9B | $3.1B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Stryker (SYK): Near-Term Growth Concerns Overshadow Long-Term Strength
2026-10-09 · Stryker (SYK) Is Changing CEOs After the Stock Fell 25% Over Twelve Months
2026-10-09 · 1 S&P 500 Stock with Solid Fundamentals and 2 We Turn Down
2026-10-09 · Leerink Partners Adjusts Stryker Price Target to $353 From $403
2026-10-08 · 1 Profitable Stock on Our Watchlist and 2 We Ignore
2026-10-08 · The Monopolistic Razor-and-Blade Engine I Can’t Stop Buying
2026-10-08 · Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates
2026-10-08 · Stryker (SYK) Stock Could Be Cheap After Its 26% Slide
2026-10-07 · Stryker (SYK) Dropped, What Is Behind The Fresh Attention?
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?
2026-10-06 · Stryker, Neogenomics Announce CEO Transitions; Both Stocks Dive
Price (daily)
Full chart · RSI · MACD · patterns